ALPHARETTA, Ga., Jan. 4, 2016 /PRNewswire/ -- EndoChoice Holdings, Inc. (NYSE: GI) announced today that Mark Gilreath, Founder and Chief Executive Officer, and David Gill, Chief Financial Officer, are scheduled to present at the J.P. Morgan 34th Annual Healthcare Conference in San Francisco, CA.
|
Event: |
J.P. Morgan 34th Annual Healthcare Conference |
|
Date: |
Wednesday, January 13, 2016 |
|
Time: |
3:30 pm PT / 6:30 pm ET |
An audio webcast of the Company's presentation will be available by visiting the investor relations section of EndoChoice's web site at www.endochoice.com. A replay of the presentation will be available for 90 days.
About EndoChoice:
Based near Atlanta, EndoChoice (NYSE: GI) is a medtech company focused on the manufacturing and commercialization of platform technologies including endoscopic imaging systems, devices and infection control products and pathology services for specialists treating a wide range of gastrointestinal conditions, including colon cancer. EndoChoice leverages its direct sales organization to serve more than 2,500 customers in the United States and works with distribution partners in 30 countries. The Company was founded in 2008 and has rapidly developed a broad and innovative product portfolio, which includes the Full Spectrum Endoscopy System (Fuse®). EndoChoice, Fuse, and Full Spectrum Endoscopy are registered trademarks of EndoChoice Holdings, Inc.
Company Contact:
David Gill, Chief Financial Officer
david.gill@endochoice.com
678-585-1040
Investor Contacts:
Nick Laudico or Zack Kubow
The Ruth Group
646-536-7030 / 7020
nlaudico@theruthgroup.com
zkubow@theruthgroup.com
SOURCE EndoChoice Holdings, Inc.